20Jul 2024
Statins Reduce Advanced Fibrosis Risk in MASLD Primary Care Patients

Statins Reduce Advanced Fibrosis Risk in MASLD Primary Care Patients

This study investigates the impact of statin use on advanced fibrosis risk in primary care patients with metabolic dysfunction-associated steatotic liver disease (MASLD). Analyzing data from 1238 patients, the research shows that statin prescriptions, especially at moderate and high intensities, are associated with a reduced risk of progressing to a high-risk FIB-4 score (≥2.67). This suggests a protective effect of statins against fibrosis progression.

  • #gastroenterology

Like

Save

Share